Latest filings (excl ownership)
6-K
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
26 Mar 24
20-F
2023 FY
Annual report (foreign)
22 Mar 24
6-K
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20 Mar 24
6-K
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18 Mar 24
6-K
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
4 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
15 Feb 24
6-K
Valneva Announces Sale of Priority Review Voucher for $103 Million
5 Feb 24
6-K
Current report (foreign)
10 Jan 24
6-K
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
8 Jan 24
6-K
Valneva Provides Updated 2023 Financial Guidance
29 Dec 23
6-K
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
21 Dec 23
6-K
Current report (foreign)
5 Dec 23
6-K
Current report (foreign)
27 Nov 23
6-K
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
15 Nov 23
6-K
Current report (foreign)
13 Nov 23
6-K
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
9 Nov 23
6-K
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
7 Nov 23
6-K
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
27 Oct 23
6-K
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
13 Oct 23
6-K
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
26 Sep 23
6-K
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
21 Sep 23
6-K
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
7 Sep 23
6-K
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
1 Sep 23
6-K
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
29 Aug 23
6-K
Valneva Announces Extension of Existing Loan Agreement
17 Aug 23
6-K
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
14 Aug 23
UPLOAD
Letter from SEC
14 Aug 23
20-F/A
2022 FY
Annual report (foreign) (amended)
10 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
UPLOAD
Letter from SEC
3 Aug 23
6-K
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
22 Jun 23
6-K
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
14 Jun 23
6-K
Current report (foreign)
31 May 23
6-K
Current report (foreign)
4 May 23
6-K
Current report (foreign)
31 Mar 23
20-F
2022 FY
Annual report (foreign)
30 Mar 23
6-K
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
23 Mar 23
6-K
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
2 Mar 23
6-K
Current report (foreign)
21 Feb 23